louis-reed-pwckf7l4-no-unsplash_5

EMA validates two applications for datopotamab deruxtecan for cancer treatments

Betsy Goodfellow | March 4, 2024 | News story | Medical Communications CHMP, Daiichi Sankyo, EMA, Oncology, datopotamab deruxtecan 

AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications (MAAs) for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd) in the treatment of two cancers.

The first MAA is for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who require systemic therapy following previous treatments.

The second MAA covers the treatment of adult patients with unresectable of metastatic hormone receptor (HR)-positive, HER2-negatice (IHC 0, IHC 1+ or IHC2+/ISH-) breast cancer who have progressed on or are not suitable for endocrine therapy and have had at least one previous systemic therapy.

These MAAs are based on data from the phase 3 TROPION-Lung01 and TROPION-Breast01 trials and commence the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP).

Susan Galbraith, executive vice president of Oncology research and development at AstraZeneca, commented: “Our ambition is for datopotamab deruxtecan to improve upon and replace conventional chemotherapy in the treatment of multiple cancer types. Today’s dual validation of our applications in lung and breast cancers brings this potential medicine a meaningful step closer to redefining treatment expectations for patients with two of the most common cancers in Europe.”

Betsy Goodfellow

Related Content

J&J gains positive CHMP opinion for Rybrevant for treatment of lung cancer

Janssen, a Johnson & Johnson (J&J) company, has announced that the Committee for Medicinal Products …

FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment

AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …

CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …

Latest content